1. Eby G, Halcomb WW. Elimination of cardiac arrhythmias using oral taurine with l-arginine with case histories: Hypothesis for nitric oxide stabilization of the sinus node. Med Hypotheses. 2006;67(5):1200-4.
2. Eby G et al. Elimination of cardiac arrhythmias using oral taurine with L-arginine with case histories: Hypothesis for nitric oxide stabilization of the sinus node. Medical Hypotheses 2006;67:1200-1204.
3. Chung MK. Vitamins, supplements, herbal medicines, and arrhythmias. Cardiol Rev. 2004;12(2):73-84.
4. Tsuji A et al. Effectiveness of oral magnesium in a patient with ventricular tachycardia due to hypomagnesemia. J Cardiovasc Pharmacol Ther. 2005;10(3):205-8.
5. He FJ et al. Beneficial effects of potassium on human health. Physiol Plant. 2008;133:725-735.
6. Alper AB et al. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009;137(1):1-8.
7. Gheeraert PJ, De Buyzere ML, Taeymans YM et al. Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic review and meta-analysis. Eur Heart J. 2006;27:2499-2510.
8. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155–61.
9. Wahr JA et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA. 1999;281:2203-2210.
10. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the commission related to the tolerable upper intake level of potassium. The EFSA Journal. 2005;193:1-19.
11. Adamopoulos C, Pitt B, Sui X et al. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol. 2009;136(3):270-7.
12. Onalan O, Crystal E, Daoulah A et al. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol. 2007;99(12):1726-32.
13. Parra L et al. Plasma magnesium in patients submitted to cardiac surgery and its influence on perioperative morbidity. J Cardiovasc Surg (Torino). 2001;42:37–42.
14. Oladapo OO et al. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. Afr J Med Med Sci. 2000;29:265–268.
15. Mathers TW et al. Oral magnesium supplementation in adults with coronary heart disease or coronary heart disease risk. J Am Acad Nurse Pract. 2009;21(12):651-7.
16. Ho KM. Intravenous magnesium for cardiac arrhythmias: jack of all trades. Magnes Res. 2008;21(1):65-8.
17. Beşoğul Y, Gemalmaz H, Aslan R. Effects of preoperative magnesium therapy on arrhythmias and myocardial ischemia during off-pump coronary surgery. Ann Thorac Med. 2009;4(3):137-9.
18. Gowda RM et al. Magnesium in treatment of acute myocardial infarction. Int J Cardiol. 2004;96(3):467-9.
19. Patsilinakos S et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010;106:673– 676.
20. Coleman CI et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009;11(7):892-5.
21. Tzivoni A et al. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol 1990;65:1397–9.
22. Kennisbank Voedselveiligheid VWA, Kennisblad magnesium, 15 juli 2008.
23. von Schacky C. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both? Curr Opin Clin Nutr Metab Care 2008;11:94-99.
24. Saravanan P et al. Cardiovascular eff ects of marine omega-3 fatty acids. Lancet 2010;375:540-550.
25. Reiffel JA et al. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006;98[suppl]:50i– 60i.
26. Aarsetoy H et al. Low levels of cellular omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 2008;78:258-264.
27. Calo L et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-1728.
28. Lau DH et al. Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure. Heart Rhythm. 2011;8(4):575-82.
29. Kumar S et al. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology. Heart Rhythm. 2011;8(4):562-8.
30. Macchia A et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol. 2008;64:627-634.
31. Kumar A et a. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther. 2009;124(3):259-68.
32. Singh RB et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347-353.
33. Baggio E et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med. 1994;15:S287-S294.
34. Fujioka T et al. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report) — antiarrhythmic action of coenzyme Q10 in diabetics. Tohoku J Exp Med. 1983;141(Suppl):453-463.
35. Singh RB et al. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J. 1996;72(843):45-50.
36. Davini P et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18(8):355-65.
37. Digiesi V et al. L-carnitine adjuvant therapy in essential hypertension. Clin Ter. 1994;144:391–395.
38. Carnes CA et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001;89:e32–8.
39. Korantzopoulos P et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005;102:321-326.
40. Ozaydin M et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J. 2008;29(5):625-31.
41. Maslov LN et al. Cardioprotective and antiarrhythmic properties of Rhodiolae roseae preparations. Eksp Klin Farmakol. 2007;70(5):59-67.
42. Maslov LN et al. Cardioprotective and antiarrhythmic properties of preparations from Leuzea carthamoides, Aralia mandshurica, and Eleutherococcus senticosus. Eksp Klin Farmakol. 2007;70(6):48-54.
43. Maslov LN et al. Antiarrhythmic activity of phytoadaptogens in short-term ischemia-reperfusion of the heart and postinfarction cardiosclerosis. Bull Exp Biol Med. 2009;147(3):331-4.
44. Holubarsch CJ et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail. 2008;10(12):1255-63.
45. Dahmer S et al. Health effects of hawthorn. Am Fam Physician 2010;81(4):465-468.
46. Garjani A et al. Effects of extracts from flowering tops of Crataegus meyeri A. Pojark on ischaemic arrhythmias in anaesthetized rats. Phytother Res. 2000;14:428–431.
47. al Makdessi S et al. Protective effect of Crataegus oxyacantha against reperfusion arrhythmias after global no-flow ischemia in the rat heart. Basic Res Cardiol. 1999;94:71–77.
48. Mashour NH et al. Herbal medicine for the treatmentnof cardiovascular disease: clinical considerations. Arch Intern Med. 1998;158:2225–2234.
49. Tauchert M et al. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure. Herz. 1999;24: 465–474; discussion 475.
50. Sungnoon R et al. Anti-arrhythmic effects of herbal medicine. Indian Heart J. 2005;57(2):109-13.
51. Sungnoon R et al. Effects of garlic on defibrillation efficacy. Int J Cardiol. 2008;126(1):143-4.
52. Sungnoon R et al. Effects of garlic on the induction of ventricular fibrillation. Nutrition 2008;24:711-716.
53. Suzuki Y et al. Effects of L-carnitine on arrhythmias during hemodialysis. Jpn Heart J. 1982;23:349–359.
54. Cacciatore L et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17:225–235.
55. Rizzon P et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur Heart J. 1989;10:502–508.
56. Beşoğul Y et al. Effects of preoperative magnesium therapy on arrhythmias and myocardial ischemia during off-pump coronary surgery. Ann Thorac Med. 2009;4(3):137-9.